Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

New Haven, Connecticut

Phase 1 colorectal cancer trials in New Haven, CT

20 Phase 1 colorectal cancer studies are recruiting participants at sites in New Haven as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

  • 20 studies are recruiting at a site in New Haven.
  • By phase: Phase 1 (10), Phase 1/2 (10).
  • By sponsor: industry (18), government (1), university, hospital or other (1).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in New Haven

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Yale University School of Medicine - Yale Cancer Center
    Registry record
    NCT05786924 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Yale University School of Medicine
    Registry record
    NCT06324357 · updated
  3. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Yale Cancer Center
    Registry record
    NCT07503808 · updated
  4. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Yale Cancer Center
    Registry record
    NCT04929223 · updated
  5. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Immunome, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07578571 · updated
  6. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Yale University School of Medicine
    Registry record
    NCT05919264 · updated
  7. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Yale Cancer Center
    Registry record
    NCT04585750 · updated
  8. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #62
    Registry record
    NCT05176483 · updated
  9. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Yale-New Haven Hospital-Yale Cancer Center
    Registry record
    NCT06445062 · updated
  10. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07349537 · updated
  11. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    Yale University Cancer Center
    Registry record
    NCT07217171 · updated
  12. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  13. Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05691491 · updated
  14. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Yale University Cancer Center
    Registry record
    NCT05719558 · updated
  15. A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alentis Therapeutics AG
    Study site
    Yale Comprehensive Cancer Center
    Registry record
    NCT07169734 · updated
  16. A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Yale University
    Registry record
    NCT07079631 · updated
  17. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Smilow Cancer Hospital (Yale University)
    Registry record
    NCT06040541 · updated
  18. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    Yale University
    Registry record
    NCT06917079 · updated
  19. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    858 Therapeutics, Inc.
    Study site
    Yale University, Yale Cancer Center
    Registry record
    NCT06395519 · updated
  20. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GV20 Therapeutics
    Study site
    Yale University
    Registry record
    NCT05669430 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call